# Merrick I. Ross

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/merrick-i-ross/

## Facts

| Field | Value |
| --- | --- |
| Citations | 58,500 |
| Field | Cutaneous Melanoma Detection and Management |
| h-index | 112 |
| i10-index | 357 |
| OpenAlex ID | https://openalex.org/A5042127830 |
| ORCID iD | https://orcid.org/0000-0002-7787-0421 |
| Works | 620 |

## Researcher papers

- [Final Version of 2009 AJCC Melanoma Staging and Classification](https://scholariq.org/papers/final-version-of-2009-ajcc-melanoma-staging-and-classification/)
- [Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma](https://scholariq.org/papers/final-version-of-the-american-joint-committee-on-cancer-staging-system-for/)
- [Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System](https://scholariq.org/papers/prognostic-factors-analysis-of-17-600-melanoma-patients-validation-of-the/)
- [Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy](https://scholariq.org/papers/clinical-course-of-breast-cancer-patients-with-complete-pathologic-primary-tumor/)
- [Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma](https://scholariq.org/papers/neoadjuvant-adjuvant-or-adjuvant-only-pembrolizumab-in-advanced-melanoma/)
- [Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma](https://scholariq.org/papers/neoadjuvant-immune-checkpoint-blockade-in-high-risk-resectable-melanoma/)
- [Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients](https://scholariq.org/papers/specific-lymphocyte-subsets-predict-response-to-adoptive-cell-therapy-using/)
- [A new American Joint Committee on Cancer staging system for cutaneous melanoma](https://scholariq.org/papers/a-new-american-joint-committee-on-cancer-staging-system-for-cutaneous-melanoma/)
- [Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases](https://scholariq.org/papers/multivariate-analysis-of-prognostic-factors-among-2-313-patients-with-stage-iii/)
- [Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience](https://scholariq.org/papers/breast-conservation-after-neoadjuvant-chemotherapy-the-m-d-anderson-cancer/)
- [Prospective Assessment of Postoperative Complications and Associated Costs Following Inguinal Lymph Node Dissection (ILND) in Melanoma Patients](https://scholariq.org/papers/prospective-assessment-of-postoperative-complications-and-associated-costs/)
- [Repair of UV Light-Induced DNA Damage and Risk of Cutaneous Malignant Melanoma](https://scholariq.org/papers/repair-of-uv-light-induced-dna-damage-and-risk-of-cutaneous-malignant-melanoma/)

## Researcher topics

- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.